Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations.

Journal Article (Editorial)

In 2009, the International Society for Heart and Lung Transplantation recognized the importance and challenges surrounding generic drug immunosuppression. As experience with generics has expanded and comfort has increased, substantial issues have arisen since that time with other aspects of immunomodulation that have not been addressed, such as access to medicines, alternative immunosuppression formulations, additional generics, implications on therapeutic drug monitoring, and implications for special populations such as pediatrics and older adults. The aim of this consensus document is to address critically each of these concerns, expand on the challenges and barriers, and provide therapeutic considerations for practitioners who manage patients who need to undergo or have undergone cardiothoracic transplantation.

Full Text

Duke Authors

Cited Authors

  • Cochrane, AB; Lyster, H; Lindenfeld, J; Doligalski, C; Baran, D; Yost, C; Shullo, M; Schweiger, M; Weill, D; Stuckey, L; Ivulich, S; Scheel, J; Peters, L; Colvin, M; Dawson, K; Girgis, R; Weeks, P; Tse, T; Russell, S; Flattery, M; Jennings, D; Kittleson, M; Miller, T; Khuu, T; Claridge, T; Uber, P; Ford, K; Ensor, CR; Simpson, K; Dipchand, A; Page, RL

Published Date

  • October 2020

Published In

Volume / Issue

  • 39 / 10

Start / End Page

  • 1050 - 1069

PubMed ID

  • 32883559

Electronic International Standard Serial Number (EISSN)

  • 1557-3117

Digital Object Identifier (DOI)

  • 10.1016/j.healun.2020.06.024


  • eng

Conference Location

  • United States